Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy
A significant proportion of human epidermal growth factor receptor 2 (Her2/ErbB2)-positive metastatic breast cancer patients are refractory to Her2-targeted trastuzumab-like therapy. Some of this resistance has been attributed to the upregulation of immune checkpoints such as programmed cell death-1...
| Váldodahkkit: | , , , , , , , |
|---|---|
| Materiálatiipa: | Artihkal |
| Giella: | English |
| Almmustuhtton: |
Taylor & Francis Group
2019-11-01
|
| Ráidu: | OncoImmunology |
| Fáttát: | |
| Liŋkkat: | http://dx.doi.org/10.1080/2162402X.2019.1648171 |